Delivery Order SPE2DB24D2101-SPE2DB25FKPPV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Clonidine HCL ER 0.1 mg tablets (60-count units) with a ceiling value of $1,187.00. This firm fixed-price delivery order, with an ultimate completion date of July 29, 2025, represents a competitively awarded, non-set-aside contract with performance executed from the contractor's Conshohocken, Pennsylvania location. The award is a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Clonidine HCL ER 0.1 mg tablets in a quantity of 60 count, with a ceiling value of $1,012.72. This is a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and was awarded through open competition without a set-aside designation. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,660.23, is for the delivery of Clonidine HCL ER 0.1 mg tablets in quantities of 60s. The award does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award, valued at $3,082.86, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of CLONIDINE HCL ER 0.1 MG TABLET 60S, a generic pharmaceutical product. The contract has an ultimate completion date of October 28, 2024 and is a firm fixed-price contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with...
- This federal contract award is a delivery order made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of clonidine hydrochloride extended-release 0.17 mg tablets in 30-count packages. The award is valued at $1,089.14 and has a performance period that extends to July 29, 2024. This contract is a firm fixed-price delivery order awarded under a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical...
- This federal contract award, with identification number SPE2DB20D3505|SPE2DB24FV0B9, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office division. The $6,706.91 firm fixed-price delivery order is for the supply of 60-count tablets of the medication Clonidine HCL ER 0.1 mg. The award has a completion date of September 16, 2024. AmerisourceBergen is a major pharmaceutical distributor that holds several Indefinite Delivery Contracts (IDCs) with federal...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Clonidine Hydrochloride Extended-Release 0.1 mg tablets. The contract is a Firm Fixed Price Delivery Order valued at $2,027.41, with an ultimate completion date of October 16, 2024. No set-aside designation was used for this award. AmerisourceBergen holds several Indefinite Delivery Contracts (IDCs) with the DLA Troop Support...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor. The $4,806.91 firm fixed-price contract is for the provision of clonidine hydrochloride extended-release 0.1 mg tablets. The award is not associated with a set-aside program. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, which serves as the primary vehicle for...
- The Defense Logistics Agency awarded a $9,520 delivery order to Amerisourcebergen Drug Corporation for 100 boxes of 0.3 mg Clonidine HCl tablets. The order was placed under an indefinite-delivery/indefinite-quantity contract vehicle to supply pharmaceutical products and services to DLA and the Department of Defense. Performance will occur at Amerisourcebergen's facility in Conshohocken, Pennsylvania by June 30, 2023. The firm fixed price order was awarded competitively with no set-aside...
- The Defense Logistics Agency awarded a $3,169 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 60 clonidine hydrochloride extended release 0.1 mg tablets. As the prime contractor, Amerisourcebergen will deliver the pharmaceutical products to a facility in Conshohocken, Pennsylvania by July 28, 2023 to support DLA's medical supply needs. Amerisourcebergen Corporation is the parent company of Amerisourcebergen Drug Corporation. No subcontractors or set aside designations...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKPPVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,159.04 to AmerisourceBergen Drug Corp for the supply of Clonidine HCL ER 0.1 mg tablets (60-count) on September 15, 2025, with an ultimate completion date of September 16, 2025. This competitive award utilizes a firm fixed-price contract structure with no set-aside designation. The product will be delivered to the vendor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, leverages its comprehensive IDC vehicle to supply a wide range of pharmaceutical products and medical supplies to military and veteran healthcare systems. As a for-profit organization registered in the System for Award Management (SAM.gov), the company has demonstrated consistent capability to meet federal procurement requirements through open competition. The DLA's broader Pharmaceutical Prime Vendor Global Program Generation V initiative, which will involve multiple awards across separate regions, reflects the strategic importance of pharmaceutical supply chains for Defense Health Agency operations and other government healthcare systems supported through flexible contract vehicles such as AmerisourceBergen's existing IDC.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/15/25 |